Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute myeloid leukaemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    406 result(s) found for: Acute myeloid leukaemia. Displaying page 8 of 21.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2013-000390-70 Sponsor Protocol Number: DACOGENAML2004 Start Date*: 2013-08-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia.
    Medical condition: Relapsed or Refractory Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Temporarily Halted) FR (Completed) NL (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000761-33 Sponsor Protocol Number: KB-ENTO-3001 Start Date*: 2022-01-03
    Sponsor Name:Kronos Bio, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults Wit...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000827-94 Sponsor Protocol Number: U-DANCE-anti-AML Start Date*: 2016-09-08
    Sponsor Name:UMC Utrecht
    Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial
    Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2009-013093-41 Sponsor Protocol Number: AC220-002 Start Date*: 2010-02-05
    Sponsor Name:Ambit Biosciences Corporation
    Full Title: A PHASE 2 OPEN-LABEL, AC220 MONOTHERAPY EFFICACY (ACE) STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH FLT3-ITD ACTIVATING MUTATIONS
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) NL (Completed) PL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003674-26 Sponsor Protocol Number: MK0457-009 Start Date*: 2007-09-03
    Sponsor Name:MERCK SHARP DOHME
    Full Title: A Phase I Dose Escalation of MK-0457 in Combination With Dasatinib in Patients With Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Medical condition: Patients with Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005719-83 Sponsor Protocol Number: ATGfamilystudy Start Date*: 2007-01-30
    Sponsor Name:University Hospital Hamburg-Eppendorf
    Full Title: Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings...
    Medical condition: acute lymphoblastic and myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024330 Leukemia acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004907-30 Sponsor Protocol Number: AG120-C-009 Start Date*: 2017-09-13
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia w...
    Medical condition: Acute Myeloid Leukemia with an IDH1 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) CZ (Completed) NL (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006881-40 Sponsor Protocol Number: AURA-6202-005 Start Date*: 2007-01-31
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy
    Medical condition: Treatment of Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000074-19 Sponsor Protocol Number: GCP#03.01.020 Start Date*: 2014-10-24
    Sponsor Name:Gamida Cell Ltd
    Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10025316 Lymphoma NOS LLT
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    17.0 100000004864 10009015 Chronic myeloid leukemia LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010548-32 Sponsor Protocol Number: CLBH589H2101 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic...
    Medical condition: Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Completed) GB (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000652-28 Sponsor Protocol Number: AIEOP_LAM_2013 Start Date*: 2015-02-04
    Sponsor Name:A.I.E.O.P.
    Full Title: Study Protocol LAM 2013/01
    Medical condition: pediatric patient with acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Newborns, Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005159-14 Sponsor Protocol Number: GC P#02.01.001 Start Date*: 2008-04-15
    Sponsor Name:Gamida Cell-Teva Joint Venture Ltd.
    Full Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in ...
    Medical condition: High-risk haematological malignancies (including AML, ALL, CML, NHL, HD, and MDS) with an indication for allogeneic haematopoietic stem cell transplantation, to support haematopoietic reconstitutio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    9.1 10009015 Chronic myeloid leukemia LLT
    9.1 10001690 ALL LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10020206 Hodgkin's disease LLT
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-001845-34 Sponsor Protocol Number: AMBIHOW Start Date*: 2011-09-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: LIPOSOMAL AMPHOTERICIN B (AMBISOME) 10 mg/kg once a week for 10 weeks as maintenance antifungal therapy for Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leuk...
    Medical condition: Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaemia and/or in Allogeneic Hematopoietic Stem Cell Transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10061730 Bone marrow transplant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10005329 - Blood and lymphatic system disorders 10028484 Mycoses fungoides HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005408-13 Sponsor Protocol Number: 2689-CL-2004 Start Date*: 2012-09-10
    Sponsor Name:Ambit BioSciences Corporation
    Full Title: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003065-15 Sponsor Protocol Number: WO29519 Start Date*: 2015-12-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTO...
    Medical condition: Relapsed or refractory acute myeloid leukemia (AML).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) NO (Completed) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001790-41 Sponsor Protocol Number: 2215-CL-0201 Start Date*: 2016-06-07
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukem...
    Medical condition: Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Completed) PL (Completed) HU (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005538-12 Sponsor Protocol Number: RG_12-264(HM2052) Start Date*: 2013-08-21
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation
    Medical condition: Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004896-38 Sponsor Protocol Number: CL1-64315-004 Start Date*: 2020-12-07
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Phase I/II, international, multicentre, open-label, non-randomised, non-comparative study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective...
    Medical condition: Acute Myeloid Leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000380-46 Sponsor Protocol Number: 75276617ALE1003 Start Date*: 2022-12-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase I/Ib Study of JNJ-75276617 in Combination with Conventional Chemotherapy for Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleo...
    Medical condition: Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    21.0 100000004864 10060354 Acute myeloblastic leukaemia LLT
    21.0 100000004864 10000833 Acute leukaemia of unspecified cell type LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001600-29 Sponsor Protocol Number: ARO-013 Start Date*: 2018-06-13
    Sponsor Name:Arog Pharmaceuticals, Inc.
    Full Title: Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Year...
    Medical condition: Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 23:08:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA